StreetInsider.com News Articles

Form 6-K Innate Pharma SA For: Jul 23

Thu, 23 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260723/26803913.html

Form 6-K Innate Pharma SA For: Jul 23

Thu, 23 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260723/26803913.html

Form 6-K Innate Pharma SA For: Jul 23

Thu, 23 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260723/26803913.html

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, Changing Treatment Landscape in Bladder Cancer, at the BTIG Virtual Biotechnology Conference.

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Thu, 23 Jul 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise

Form 6-K Innate Pharma SA For: Jul 21

Tue, 21 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26791667.html

Form 6-K Innate Pharma SA For: Jul 21

Tue, 21 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26791667.html

Form 6-K Innate Pharma SA For: Jul 21

Tue, 21 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26791667.html

Innate Pharma completes enrollment in Phase 1 IPH4502 ADC study

Tue, 21 Jul 2026 01:00:17 -0400

Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced the completion of enrollment in the dose escalation portion of its Phase 1 study of IPH4502, a Nectin-4 exatecan antibody-drug conjugate (ADC), with preliminary data from 76 patients expected by year-end.

The IPH4502-101 study is an open-label, multi-center trial evaluating the safety, tolerability, and preliminary anti-tumor activity of IPH4502 as a single agent in patients with advanced solid tumors known to express Nectin-4. Eligible tumor types include urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast, ovarian, gastric, esophageal, and colorectal cancers. The 76 patients were

Innate Pharma completes enrollment in Phase 1 IPH4502 ADC study

Tue, 21 Jul 2026 01:00:17 -0400

Innate Pharma completes enrollment in Phase 1 IPH4502 ADC study

Tue, 21 Jul 2026 01:00:17 -0400

Innate Pharma completes enrollment in Phase 1 IPH4502 ADC study

Tue, 21 Jul 2026 01:00:17 -0400

Innate Pharma completes enrollment in Phase 1 IPH4502 ADC study

Tue, 21 Jul 2026 01:00:17 -0400

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Tue, 21 Jul 2026 01:00:00 -0400

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
Favorable safety profile observed to date, with limited hematological toxicity
Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Tue, 21 Jul 2026 01:00:00 -0400

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
Favorable safety profile observed to date, with limited hematological toxicity
Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Tue, 21 Jul 2026 01:00:00 -0400

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
Favorable safety profile observed to date, with limited hematological toxicity
Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Tue, 21 Jul 2026 01:00:00 -0400

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
Favorable safety profile observed to date, with limited hematological toxicity
Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: